LLY

1,083.28

+0.8%↑

JNJ

231.62

+0.37%↑

ABBV

214.82

+1.19%↑

UNH

381

+0.29%↑

MRK

120.64

+0.1%↑

LLY

1,083.28

+0.8%↑

JNJ

231.62

+0.37%↑

ABBV

214.82

+1.19%↑

UNH

381

+0.29%↑

MRK

120.64

+0.1%↑

LLY

1,083.28

+0.8%↑

JNJ

231.62

+0.37%↑

ABBV

214.82

+1.19%↑

UNH

381

+0.29%↑

MRK

120.64

+0.1%↑

LLY

1,083.28

+0.8%↑

JNJ

231.62

+0.37%↑

ABBV

214.82

+1.19%↑

UNH

381

+0.29%↑

MRK

120.64

+0.1%↑

LLY

1,083.28

+0.8%↑

JNJ

231.62

+0.37%↑

ABBV

214.82

+1.19%↑

UNH

381

+0.29%↑

MRK

120.64

+0.1%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

2.35 9.81

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.1

Max

2.43

Põhinäitajad
By Trading Economics
Sissetulek	1.2M -31M
Müük	-70K 1.3M
Aktsiakasum	-0.26
Kasumimarginaal	-2,402.848
Töötajad	161
EBITDA	12M -30M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+105.58% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. aug 2026

Turustatistika
By TradingEconomics
Turukapital	8.8M 262M
Eelmine avamishind	-7.46
Eelmine sulgemishind	2.35

Uudiste sentiment

By Acuity

50%

154 / 344 Pingereas Healthcare

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. mai 2026, 16:52 UTC

Uudisväärsed sündmused

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q Rev $1.76B >SQM

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q EPS $1.28 >SQM

26. mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q EPS $11.61 >WEBC

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q Sales $179.6M >WEBC

26. mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26. mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26. mai 2026, 20:58 UTC

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26. mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26. mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26. mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26. mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26. mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26. mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26. mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26. mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26. mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26. mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

26. mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26. mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26. mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

105.58% tõus

12 kuu keskmine prognoos

Keskmine 4.42 USD 105.58%

Kõrge 7 USD

Madal 2.2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

154 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.